Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Optimising Analysis of Stroke Trials Collaboration, OAST (2007)
Publisher: American Heart Association Inc
Languages: English
Types: Article
Background: Most large acute stroke trials have been neutral. Functional outcome is usually analysed using a yes or no answer, e.g. death or dependency vs. independence. We assessed which statistical approaches are most efficient in analysing outcomes from stroke trials.\ud \ud Methods: Individual patient data from acute, rehabilitation and stroke unit trials studying the effects of interventions which alter functional outcome were assessed. Outcomes included modified Rankin Scale, Barthel Index, and ‘3 questions’. Data were analysed using a variety of approaches which compare two treatment groups. The results for each statistical test for each trial were then compared.\ud \ud Results: Data from 55 datasets were obtained (47 trials, 54,173 patients). The test results differed substantially so that approaches which use the ordered nature of functional outcome data (ordinal logistic regression, t-test, robust ranks test, bootstrapping the difference in mean rank) were more efficient statistically than those which collapse the data into 2 groups (chi square) (ANOVA p<0.001). The findings were consistent across different types and sizes of trial and for the different measures of functional outcome. \ud \ud Conclusions: When analysing functional outcome from stroke trials, statistical tests which use the original ordered data are more efficient and more likely to yield reliable results. Suitable approaches included ordinal logistic regression, t-test, and robust ranks test.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute stroke. N Engl J Med. 1995;333:1581-1587.
    • 2. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke. Lancet. 1997;349:1641-1649.
    • 3. Walker M, Gladman J, Lincoln N, Siemonsma P, Whiteley T. Occupational therapy for stroke patients not admitted to hospital: a randomised controlled trial. The Lancet. 1999;354:278 -280.
    • 4. Chen ZM, Sandercock P, Pan HC, Counsell C, Collins R, Liu LS, Xie JX, Warlow C, Peto R; on behalf of the CAST and IST Collaborative Groups. Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. Stroke. 2000;31:1240 -1249.
    • 5. Stroke Unit Trialists' Collaboration. Organised inpatient (stroke unit) care for stroke. The Cochrane Library. Oxford: Update Software; 2002.
    • 6. The ATLANTIS ECASS and NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA Stroke trials. The Lancet. 2004; 363:768 - 813.
    • 7. Walker MF, Leonardi-Bee J, Bath P, Langhorne P, Corr S, Drummond A, Gilbertson L, Gladman JRF, Jongbloed L, Parker C. An individual patient data meta-analysis of randomised controlled trials of community occupational therapy for stroke patients. Stroke. 2004;35:2226 -2232.
    • 8. Saxena R, Wijnhoud AD, Carton H, Hacke W, Kaste M, Przybelski RJ, Stern KN, Koudstaal PJ. Controlled safety study of a hemoglobin-based oxygen carrier, DCLHB, in acute ischemic stroke. Stroke. 1999;30: 993-996.
    • 9. Davis SM, Lees KR, Albers GW, Diener HC, Markabi S, Karlsson G, Norris J; for the ASSIST Investigators. Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke. 2000;31: 347-354.
    • 10. Enlimomab acute stroke trial investigators. Use of anti-ICAM-1 therapy in ischemic stroke: results of the enlimomab acute stroke trial. Neurology. 2001;57:1428 -1434.
    • 11. Bath PMW, Blecic S, Bogousslavsky J, Boysen G, Davis S, Diez-Tejedor E, Ferro JM, Gommans J, Hacke W, Indredavik B, Norrving B, Orgogozo JM, Ringelstein EB, Sacchetti ML, Idddenden R, Bath FJ, Musch BC, Brosse DM, Naberhuis-Stehouwer SA. Tirilazad mesylate in acute ischemic stroke: a systematic review. Stroke. 2000;31:2257-2265.
    • 12. Grotta J. Why do all drugs work in animals but none in stroke patients? 2 neuroprotective therapy. J Intern Med. 1995;237:89 -94.
    • 13. Weaver CS, Leonardi-Bee J, Bath-Hexall FJ, Bath PMW. Sample size calculations in acute stroke trials: a systematic review of their reporting, characteristics, and relationship with outcome. Stroke. 2004;35: 1216 -1224.
    • 14. Rankin J. Cerebral vascular accidents in patients over the age of 60. 2. Prognosis. Scott Med J. 1957;2:200 -215.
    • 15. Mahoney FI, Barthel DW. Functional evaluation: The Barthel Index. Maryland State Medical Journal. 1965:61- 65.
    • 16. Lindley RI, Waddell F, Livingstone M, Sandercock P, Dennis MS, Slattery J, Smith B, Warlow C. Can simple questions assess outcome after stroke? Cerebrovascular Diseases. 1994;4:314 -324.
    • 17. Bath P, Lindenstrom E, Boysen G, De Deyn P, Friis P, Leys D, Marttila R, Olsson J-E, O'Neill D, Orgogozo J-M, Ringelstein B, van der Sande J-J, Turpie AGG. Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet. 2001;358:702-710.
    • 18. Horn J, deHaan R, Vermeulen M, Limburg M. Very early nimodipine use in stroke (VENUS): a randomised, double-blind, placebo-controlled trial. Stroke. 2001;32:461- 465.
    • 19. Wardlaw J, Sandercock P, Warlow C, Lindley RI. Trials of thrombolysis in acute ischemic stroke: does the choice of primary outcome measure really matter? Stroke. 2000;31:1133-1135.
    • 20. Hacke W, Markku K, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352:1245-1251.
    • 21. Stingele R, Bluhmki E, Hacke W. Bootstrap statistics of ECASS II data: just another post hoc analysis of a negative stroke trial? Cerebrovascular Diseases. 2001;11:30 -33.
    • 22. Haley EC. High-dose tirilazad for acute stroke (RANTTAS II). Stroke. 1998;29:1256 -1257.
    • 23. The RANTTAS Investigators. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). Stroke. 1996;27:1453-1458.
    • 24. The STIPAS Investigators. Safety study of tirilazad mesylate in patients with acute ischemic stroke (STIPAS). Stroke. 1994;25:418 - 423.
    • 25. The Tirilazad International Steering Committee. Tirilazad for acute ischaemic stroke (cochrane review). Oxford: Update Software; 2002.
    • 26. Barer DH, Cruickshank JM, Ebrahim SB, Mitchell JR. Low dose beta blockade in acute stroke (“Best” Trial): an evaluation. BMJ. 1988;296: 737-741.
    • 27. Shannon CE. A mathematical therory of communication. The Bell System Technical Journal. 1948;27:379 - 423.
    • 28. The Multicenter Acute Stroke Trial; Europe Study Group. Thrombolytic therapy with Streptokinase in acute ischemic stroke. N Engl J Med. 1996; 335:145-149.
    • 29. Adams HP, Leclerc JR, Bluhmki E, Clarke WR, Hansen MD, Hacke W. Measuring outcomes as a function of baseline severity of ischemic stroke. Cerebrovascular Diseases. 2004;18:124 -129.
    • 30. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener H-C, Grotta J, Lyden P, Shuaib A, Hardernark H-G, Wasiewski WW; for the Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354:588 - 600.
    • 31. Whitehead J. Sample-size calculations for ordered categorical-data. Statistics in Medicine. 1993;12:2257-2271.
  • No related research data.
  • No similar publications.

Share - Bookmark

Cite this article